Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.

ABSTRACT: Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the major mechanisms of chemotherapy resistance. We designed an open-label phase II clinical trial to evaluate if the combination of everolimus (mTOR inhibitor) plus cisplatin (interferes with DNA function) will improve the rate of pathologic response, as assessed by residual cancer burden (RCB). Twenty-four Stage II/III TNBC patients with residual cancer > 1 cm post neoadjuvant anthracycline and taxane-based chemotherapy were enrolled. Patients received everolimus daily orally at 10 mg for 12 weeks and cisplatin IV at 20 mg/m² weekly for 4 cycles (21-day cycle), until defin

SUBMITTER: Anand K 

PROVIDER: S-EPMC7794349 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature